The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Skin Exam Advised Before Anti-TNF-Alpha Therapy

Skin Exam Advised Before Anti-TNF-Alpha Therapy

January 16, 2018 • By Rita Buckley

  • Tweet
  • Email
Print-Friendly Version / Save PDF

NEW YORK (Reuters Health)—Using tumor necrosis factor alpha (TNF-alpha) inhibitors for atypical dermatoses may unmask, or perhaps even worsen, cutaneous lymphoma, according to new research.

You Might Also Like
  • Skin Complications of Anti-TNF Therapy Common in IBD
  • Anti-TNF-Associated Skin Lesions Common in Inflammatory Bowel Disease
  • Anti-TNF-Alpha Agents May Improve Endothelial Function Patients with RA

“Our findings suggest that careful skin examination might be required in all patients prescribed anti-TNF-alpha agents, especially those with atypical presentations of benign skin conditions,” says Dr. Joan Guitart of Northwestern University Feinberg School of Medicine in Chicago. She recommended that these patients undergo skin biopsy plus specific peripheral blood work-up.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“When a skin lymphoma cannot be completely ruled out, physicians should consider alternative therapies or closely monitor patients after the start of anti-TNF-alpha treatment,” Dr. Guitart tells Reuters Health by email.

For the study, online Jan. 4 in the Journal of the American Academy of Dermatology, Dr. Guitart and colleagues did a chart review for patients diagnosed with cutaneous lymphoma at their institution after initiation of anti-TNF-alpha therapy and also reviewed the literature.1

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

They identified 22 patients (15 male and seven female); 18 had a skin disorder prior to treatment and 15 had a biopsy. The most common histologic findings, seen in 10 patients, were psoriasis or psoriasiform dermatitis.

After treatment with anti-TNF-alpha, 20 (90%) patients were diagnosed with cutaneous T-cell lymphomas and two (9%) with indolent cutaneous B-cell lymphomas. Mycosis fungoides and Sezary syndrome were the most common subtypes of cutaneous T-cell lymphoma.

For 15 patients (75%), the indication for anti-TNF-alpha therapy was a presumed inflammatory skin disorder, most commonly psoriasis, psoriasiform dermatitis, or idiopathic erythroderma.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Five (25%) patients were diagnosed with either rheumatoid arthritis, Crohn’s disease, or sarcoidosis; three of these had a concomitant but unspecified dermatitis prior to the start of immunosuppressant therapy.

The median time from the start of anti-TNF-alpha agents to the diagnosis of cutaneous T-cell lymphoma was six months (range: 1–24).

Three patients died from their cutaneous T-cell lymphoma; one did so two months after the start of anti-TNF-alpha therapy.

Both patients with cutaneous B-cell lymphoma achieved complete remission.

The literature search identified an additional 31 cases.

Twenty (65%) patients received an anti-TNF-alpha agent to treat a systemic disease (e.g., rheumatoid arthritis, irritable bowel syndrome); six had a concurrent and poorly characterized skin disorder.

Among the 17 patients with any kind of dermatosis, less than half had a biopsy prior to the start of anti-TNF-alpha treatment, or had one with inconclusive results.

“Our findings suggest that most of the identified patients were misdiagnosed as having psoriasis or eczema; therefore, a comprehensive morphological and molecular review of skin biopsies and peripheral blood should be considered prior to initiation of anti-TNF-alpha therapy in patients with poorly defined dermatitis or atypical presentations of “psoriasis”,” the researchers write.

Pages: 1 2 | Single Page

Filed Under: DMARDs & Immunosuppressives, Drug Updates Tagged With: Anti-TNF, Anti-TNF-Alpha, Cancer, cutaneous lymphoma, psoriasiform dermatitis, Psoriasis, skin, skin disease

You Might Also Like:
  • Skin Complications of Anti-TNF Therapy Common in IBD
  • Anti-TNF-Associated Skin Lesions Common in Inflammatory Bowel Disease
  • Anti-TNF-Alpha Agents May Improve Endothelial Function Patients with RA
  • Increased Risk of Serious Infections During Early Anti-TNF Treatment

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)